Litigation against incretin mimetics producers for the product’s link to pancreatic cancer in Type 2 Diabetics is expected to proceed as an MDL.
After many years of working its way through the court system, the United States Court of Appeals for the Ninth Circuit reversed a lower court’s decision. The appeals court ruled that the trial court should have more thoroughly considered information about the drug.
Next steps for the MDL are currently under consideration.
Source: The National Law Review